Pharmacist Digest

STAT+: Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

STAT

MARCH 15, 2024

German pharmaceutical company Bayer is expanding its U.S. Bayer’s C-suite has been on a soul-searching mission for the last year, spurred by new leadership and the realization that the company is, as new CEO Bill Anderson said earlier this month, “ badly broken.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies

Bayer secures full ownership of Bayer Zydus Pharma, acquires remaining 25 per cent stakes

Express Pharma

MAY 2, 2024

Bayer Pharmaceuticals and Zydus Lifesciences announced the successful conclusion of their joint venture (JV) – Bayer Zydus Pharma. Bayer is now securing full ownership of the entity, as per pre-agreed JV terms.

Diabetes

Bayer cutbacks start to be felt with 1,500 jobs shed in Q1

pharmaphorum

MAY 14, 2024

Bayer's first-quarter results update shows its headcount has shrunk by around 1,500 since the start of the year, suggesting promised job cuts are starting to take hold

Bayer Pharmaceuticals accelerates innovations for patients

LifeProNow

MARCH 27, 2023

March 24,2023: “At its annual Pharma Media Day 2023, Bayer presented the latest progress in the ongoing transformation of its pharmaceutical business focusing on accelerating innovative healthcare solutions for the benefits of patients and delivering long-term, sustainable business growth.

Bioethics

Bioethics Compounding Diabetes

STAT+: Bayer, facing investor ire, appoints an outsider CEO

STAT

FEBRUARY 8, 2023

Bayer named former Roche executive Bill Anderson as its new CEO on Wednesday, potentially ending a dramatic and difficult chapter during which its current chief executive, Werner Baumann, presided over the disastrous $63 billion purchase of the agriculture firm Monsanto.

STAT+: Bayer agrees to $40 million settlement over kickbacks and downplaying drug safety risks

STAT

SEPTEMBER 6, 2022

After nearly two decades of litigation, Bayer agreed to pay $40 million to settle a pair of whistleblower lawsuits that accused the company of paying kickbacks to doctors and hospitals, as well as marketing two medicines for unapproved uses and downplaying safety risks of two other drugs. Continue to STAT+ to read the full story…

Hospitals

Bayer details layoffs as company shake-up continues

BioPharma Dive

MAY 14, 2024

The reduction of 1,500 roles in the first quarter is part of CEO Bill Anderson’s plan to shrink Bayer’s bureaucracy and “radically realign” its culture.

Bayer and Evotec to collaborate on precision cardiology

Pharmafile

APRIL 30, 2024

Bayer and Evotec have announced that they have updated the focus of their collaboration to work on the development of innovative precision treatments for cardiovascular diseases (CVDs). The post Bayer and Evotec to collaborate on precision cardiology appeared first on Pharmafile.

Bayer expands global life science incubator network

World Pharma News

NOVEMBER 7, 2023

Bayer AG today announced the global expansion of its life science incubator network, Bayer Co.Lab, to Shanghai, China, and Kobe, Japan. This move establishes new sites for the Bayer Co.Lab program at the hotspots of innovation in China as well as in Japan.

Bayer extends Partnership with Peking University to foster Pharmaceutical Innovation in China

LifeProNow

JULY 14, 2023

July 10, 2023 : “Bayer and Peking University (PKU) will collaborate to foster the translation of basic pharmaceutical research into drug discovery and development, while accelerating scientific research on cutting-edge technologies across the pharmaceutical value chain.

Bayer and Recursion focus research collaboration on oncology

World Pharma News

NOVEMBER 10, 2023

Bayer and US-based Recursion Pharmaceuticals, Inc., The oncology-focused collaboration will leverage Bayer's small molecule compound library and expertise in biology and medicinal chemistry as well as Recursion’s purpose-built artificial intelligence-guided drug discovery platform.

Compounding

Bayer and Aignostics to collaborate on next generation precision oncology

World Pharma News

MARCH 15, 2024

Bayer and Aignostics GmbH announced a strategic collaboration on several artificial intelligence (AI)-powered approaches with applications in precision oncology drug research and development.

Hospitals

Bayer, Google partner on AI for time-pressed radiologists

pharmaphorum

APRIL 9, 2024

Bayer enlists the aid of Google Cloud to develop its AI platform for radiologists, adding genAI capabilities

Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines

World Pharma News

MARCH 20, 2024

Bayer AG and Thermo Fisher Scientific Inc. These will help identify patients who may benefit from Bayer's growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time.

Shweta Rai appointed as new MD of Bayer Zydus Pharma

Express Pharma

DECEMBER 18, 2023

Manoj Saxena will move out of his present role to take on the role of CDH for Bayer’s Pharmaceuticals Division and Senior Bayer Representative, Bayer Group for the Australia & New Zealand (ANZ) cluster, with effect from the same date. Shweta joined Bayer in 2019 and her last assignment was Business Unit Head.

Diabetes

Diabetes Vaccines

Thermo Fisher, Bayer partner to develop companion diagnostics

BioPharma Dive

MARCH 21, 2024

The companies aim to identify potential patients for Bayer’s precision cancer therapies and increase access to the treatments.

Could Bayer's non-hormonal elinzanetant signal the end of menopausal hot flushes?

Outsourcing Pharma

MAY 17, 2024

Bayer announced today (May 17) that it will showcase its results of two phase 3 studies that could combat hot flushes for menopausal women.

Bayer takes novel deep vein thrombosis drug into phase 2

pharmaphorum

FEBRUARY 20, 2024

Bayer takes anti-alpha2 antiplasmin antibody BAY3018250 into phase 2 as a deep vein thrombosis treatment, hoping to improve on thrombolytics.

New patent expiration for Bayer Healthcare drug ALIQOPA

Drug Patent Watch

MAY 12, 2024

Annual Drug Patent Expirations for ALIQOPA Aliqopa is a drug marketed by Bayer Healthcare and is included in one NDA. It is available from one supplier. There are four patents… Source

Bayer cues up filings for rival to Astellas’ menopause drug

pharmaphorum

MARCH 19, 2024

New phase 3 data sets up filings for Bayer's non-hormonal menopause symptom treatment elinzanetant and a challenge to Astellas’ first-to-market Veozah

Bayer signs marketing and distribution agreement with Dr Reddy’s for second brand of Vericiguat in India

Express Pharma

APRIL 6, 2024

Under the terms of this agreement, Bayer has granted non-exclusive rights to Dr Reddy’s under the brand name Gantra. The partnership with Bayer is part of Dr Reddy’s continuous efforts to make innovative medicines available to patients in India through strategic collaborations.

Hospitals

Bayer's AskBio initiates Phase II GenePHIT trial in Congestive Heart Failure (CHF)

World Pharma News

JANUARY 12, 2024

Bayer AG and Asklepios BioPharmaceutical, Inc. AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, have announced the initiation of GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002 (also known as NAN-101) for the treatment of congestive heart failure (CHF).

Bayer, Astellas switch CEOs amid major inflection points

PharmaVoice

FEBRUARY 9, 2023

Bayer’s Bill Anderson and Astellas’ Naoki Okamura will be charged with setting the companies on growth trajectories for 2023.

Bayer CEO pulls back from breakup of ‘badly broken’ group

pharmaphorum

MARCH 6, 2024

Bayer CEO says company is “badly broken” by patent losses, litigation, debt levels, and bureaucracy, limiting its options for a break-up of the group.

Bayer, Sun Pharma sign marketing and distribution pact for second brand of Finerenone

Express Pharma

JANUARY 17, 2024

Sun Pharmaceutical Industries and Bayer have signed an agreement to market and distribute a second brand of Finerenone in India. Under the terms of the agreement, Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa.

Diabetes

Bayer pays $310m for Euro rights to ATTR therapy acoramidis

pharmaphorum

MARCH 4, 2024

Bayer licenses European rights to BridgeBio's acoramidis, putting some big pharma muscle behind the ATTR cardiomyopathy treatment

Astellas and Bayer announce management changes

European Pharmaceutical Review

FEBRUARY 10, 2023

Changes to management for Big Pharma companies Astellas and Bayer AG have been announced for 2023. He has experience in the commercial area at Schering and Bayer. Bill Anderson to become CEO of Bayer AG Bayer AG ’s Supervisory Board has appointed Bill Anderson as the company’s new CEO, effective June 1, 2023.

Bayer launches support tool for diabetic kidney disease

pharmaphorum

NOVEMBER 1, 2023

Bayer launches support tool for diabetic kidney disease Phil.Taylor Wed, 01/11/2023 - 11:19 Bookmark this

Diabetes

New patent for Bayer Hlthcare drug KERENDIA

Drug Patent Watch

MARCH 4, 2024

Annual Drug Patent Expirations for KERENDIA Kerendia is a drug marketed by Bayer Hlthcare and is included in one NDA. There is one patent… The post New patent for Bayer Hlthcare drug KERENDIA appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

Bayer reports drop in Q1 sales amidst patent litigation challenges

Pharmaceutical Technology

MAY 14, 2024

Bayer announced a fall in Q1 sales and predicted future challenges in the Xarelto market in its Q1 update.

Bayer and Aignostics to collaborate for AI oncology research

Pharmafile

MARCH 14, 2024

Bayer and Aignostics have announced that they have entered into a strategic collaboration for several artificial intelligence (AI)-powered approaches for precision oncology drug research and development.

New patent for Bayer Hlthcare drug MIRENA

Drug Patent Watch

MARCH 1, 2024

Annual Drug Patent Expirations for MIRENA Mirena is a drug marketed by Bayer Hlthcare and is included in one NDA. There are four patents… The post New patent for Bayer Hlthcare drug MIRENA appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

New patent for Bayer Hlthcare drug SKYLA

Drug Patent Watch

MARCH 1, 2024

Annual Drug Patent Expirations for SKYLA Skyla is a drug marketed by Bayer Hlthcare and is included in one NDA. There are six patents… The post New patent for Bayer Hlthcare drug SKYLA appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

New patent for Bayer Hlthcare drug KYLEENA

Drug Patent Watch

MARCH 1, 2024

Annual Drug Patent Expirations for KYLEENA Kyleena is a drug marketed by Bayer Hlthcare and is included in one NDA. There are six patents… The post New patent for Bayer Hlthcare drug KYLEENA appeared first on DrugPatentWatch - Make Better Decisions. It is available from one supplier.

Bayer pulls atrial fibrillation study for asundexian

pharmaphorum

NOVEMBER 20, 2023

Bayer pulls atrial fibrillation study for asundexian Phil.Taylor Mon, 20/11/2023 - 10:13 Bookmark this

Bayer aims to sustainably improve performance with new organization

World Pharma News

JANUARY 23, 2024

The Bayer Group is introducing a new operating model called "Dynamic Shared Ownership" (DSO) worldwide, which will reduce hierarchies, eliminate bureaucracy, streamline structures and accelerate decision-making processes.

Bayer and Evotec link to develop precision cardiology therapeutics

Pharmaceutical Technology

MAY 1, 2024

Bayer and Evotec have expanded collaboration to focus on the development of precision treatments for cardiovascular diseases (CVDs).

New patent expiration for Bayer Hlthcare drug LEVITRA

Drug Patent Watch

JULY 2, 2023

Annual Drug Patent Expirations for LEVITRA Levitra is a drug marketed by Bayer Hlthcare and is included in one NDA. There are two patents protecting this drug and three Paragraph… The post New patent expiration for Bayer Hlthcare drug LEVITRA appeared first on DrugPatentWatch - Make Better Decisions.

Bayer extends elinzanetant trials to include breast cancer

pharmaphorum

OCTOBER 17, 2022

Bayer has added another clinical trial to its extensive phase 3 programme for oral neurokinin antagonist elinzanetant, hoping to show that it can treat vasomotor symptoms (VMS) in breast cancer patients. The post Bayer extends elinzanetant trials to include breast cancer appeared first on.

Bayer expands German manufacturing facilities to fulfill supply demand

Pharmaceutical Technology

NOVEMBER 24, 2023

Bayer announced the launch of a Berlin, Germany-based manufacturing facility to meet future demands from the US, China and Europe.

Bayer and Google Cloud to develop AI solutions for radiologists

Pharmaceutical Technology

APRIL 10, 2024

Bayer has partnered with Google Cloud to develop AI-powered solutions for radiologists, creating scalable and compliant imaging software.

Bayer taps Google’s quantum power for drug discovery

pharmaphorum

JANUARY 12, 2023

Bayer has signed an agreement with Google aimed at using high-level processing power to handle quantum chemistry calculations used to predict the chemical and physical properties of drug molecules at the atomic scale. The post Bayer taps Google’s quantum power for drug discovery appeared first on. Image source: Google.

Bayer invests 130 million EUR in new production facility for innovative parenteral products

World Pharma News

NOVEMBER 23, 2023

Bayer has added a brand new manufacturing facility to its global supply chain network. The new production plant was inaugurated today at the company's global pharmaceutical headquarters in Berlin, Germany. The facility features state-of-the-art technology, innovative production, and automated processes.

German union will resist any plan to split up Bayer

pharmaphorum

JANUARY 15, 2024

Germany’s IG BCE trade union has pushed back against any break-up of Bayer, claiming it could put thousands of domestic jobs at risk

STAT+: Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Bayer secures full ownership of Bayer Zydus Pharma, acquires remaining 25 per cent stakes

Trending Sources

Bayer cutbacks start to be felt with 1,500 jobs shed in Q1

Bayer Pharmaceuticals accelerates innovations for patients

STAT+: Bayer, facing investor ire, appoints an outsider CEO

STAT+: Bayer agrees to $40 million settlement over kickbacks and downplaying drug safety risks

Bayer details layoffs as company shake-up continues

Bayer and Evotec to collaborate on precision cardiology

Bayer expands global life science incubator network

Bayer extends Partnership with Peking University to foster Pharmaceutical Innovation in China

Bayer and Recursion focus research collaboration on oncology

Bayer and Aignostics to collaborate on next generation precision oncology

Bayer, Google partner on AI for time-pressed radiologists

Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines

Shweta Rai appointed as new MD of Bayer Zydus Pharma

Thermo Fisher, Bayer partner to develop companion diagnostics

Could Bayer's non-hormonal elinzanetant signal the end of menopausal hot flushes?

Bayer takes novel deep vein thrombosis drug into phase 2

New patent expiration for Bayer Healthcare drug ALIQOPA

Bayer cues up filings for rival to Astellas’ menopause drug

Bayer signs marketing and distribution agreement with Dr Reddy’s for second brand of Vericiguat in India

Bayer's AskBio initiates Phase II GenePHIT trial in Congestive Heart Failure (CHF)

Bayer, Astellas switch CEOs amid major inflection points

Bayer CEO pulls back from breakup of ‘badly broken’ group

Bayer, Sun Pharma sign marketing and distribution pact for second brand of Finerenone

Bayer pays $310m for Euro rights to ATTR therapy acoramidis

Astellas and Bayer announce management changes

Bayer launches support tool for diabetic kidney disease

New patent for Bayer Hlthcare drug KERENDIA

Bayer reports drop in Q1 sales amidst patent litigation challenges

Bayer and Aignostics to collaborate for AI oncology research

New patent for Bayer Hlthcare drug MIRENA

New patent for Bayer Hlthcare drug SKYLA

New patent for Bayer Hlthcare drug KYLEENA

Bayer pulls atrial fibrillation study for asundexian

Bayer aims to sustainably improve performance with new organization

Bayer and Evotec link to develop precision cardiology therapeutics

New patent expiration for Bayer Hlthcare drug LEVITRA

Bayer extends elinzanetant trials to include breast cancer

Bayer expands German manufacturing facilities to fulfill supply demand

Bayer and Google Cloud to develop AI solutions for radiologists

Bayer taps Google’s quantum power for drug discovery

Bayer invests 130 million EUR in new production facility for innovative parenteral products

German union will resist any plan to split up Bayer

Stay Connected